Vaxcyte Inc (PCVX) Stock Price, Quote & News

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 0111

Website: vaxcyte.com

Address:

825 Industrial Road, Suite 300, San Carlos, United States

CapitalMonk May. 13 at 4:32 AM

$PCVX Price: $54.03 (+0.07%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.40% RSI: 31.6 | Momentum: Strong Downside Volume: -12.8% vs avg Volatility: 3.07% Support: $48.49 | Resistance: $63.31 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

cubie May. 12 at 4:29 PM

$PCVX yea interesting

0 · Reply

RandyRanderson1 May. 12 at 4:00 PM

@cubie $PCVX Any thoughts on the options trading going on here? Looks like the same trader active across the Oct and Dec. Thanks!

1 · Reply

OfficialStocktwitsUser Apr. 10 at 3:02 AM

$PCVX RSI: 72.45, MACD: 1.0503 Vol: 2.51, MA20: 56.58, MA50: 56.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

NorthStarStats Apr. 1 at 1:45 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $CSX Score 100, $NUVL Score 100, $AZN Score 100, $WAB Score 100, $PCVX Score 98

0 · Reply

greensmell Mar. 7 at 4:42 AM

$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw

0 · Reply

KY3000 Mar. 7 at 12:02 AM

$PCVX HMPV, no vaccine can treat it, this should be their next target

0 · Reply

BillionerOfKing Mar. 3 at 2:34 AM

$PCVX Current Stock Price: $61.97 Contracts to trade: $60.0 PCVX Mar 20 2026 Call Entry: $3.90 Exit: $7.48 ROI: 92% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

KY3000 Feb. 28 at 7:14 PM

$PCVX don’t worry about production

0 · Reply

KY3000 Feb. 25 at 10:34 PM

$PCVX needs to announce another target, they going to be commercialized sooner than later

0 · Reply

Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T01:27:16.000Z - 6 days ago

Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)

May 6, 2026, 4:05 PM EDT - 6 days ago

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 14, 2026, 2:15 PM EDT - 4 weeks ago

Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 4:05 PM EDT - 5 weeks ago

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-23T13:06:31.000Z - 7 weeks ago

Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial

Mar 23, 2026, 8:30 AM EDT - 7 weeks ago

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

2026-03-18T23:45:17.000Z - 7 weeks ago

Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet

Mar 18, 2026, 7:34 PM EDT - 7 weeks ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Mar 9, 2026, 1:00 PM EDT - 2 months ago

Vaxcyte Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 2 months ago

Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T01:15:13.000Z - 2 months ago

Vaxcyte price target raised to $89 from $85 at BTIG

2026-02-25T15:10:32.000Z - 2 months ago

Vaxcyte price target lowered to $133 from $134 at BofA

2026-02-25T13:06:55.000Z - 2 months ago

Vaxcyte price target raised to $67 from $38 at Goldman Sachs

2026-02-25T12:50:02.000Z - 2 months ago

Vaxcyte price target raised to $75 from $50 at TD Cowen

2026-02-24T21:38:10.000Z - 2 months ago

Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year

Feb 24, 2026, 4:30 PM EST - 2 months ago

Vaxcyte Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:05 PM EST - 2 months ago

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 12, 2026, 1:30 PM EST - 3 months ago

Vaxcyte Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-11T21:30:50.000Z - 3 months ago

Vaxcyte doses first participants in OPUS-3 trial

Feb 11, 2026, 4:05 PM EST - 3 months ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Feb 10, 2026, 4:05 PM EST - 3 months ago

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Feb 5, 2026, 4:05 PM EST - 3 months ago

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 2, 2026, 4:05 PM EST - 3 months ago

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-01-30T11:06:07.000Z - 3 months ago

Vaxcyte 11M share Spot Secondary priced at $50.00

Jan 29, 2026, 11:33 PM EST - 3 months ago

Vaxcyte Announces Pricing of $550 Million Public Offering

2026-01-30T00:45:09.000Z - 3 months ago

Vaxcyte secondary being re-offered at $50 per share

2026-01-29T22:55:17.000Z - 3 months ago

Vaxcyte offering marketed at $50 per share, Bloomberg says

2026-01-29T21:11:25.000Z - 3 months ago

Vaxcyte announces offering of $500M of common stock and warrants

Jan 29, 2026, 4:06 PM EST - 3 months ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-01-22T22:10:28.000Z - 3 months ago

Vaxcyte provides update on development of VAX-31 pneumococcal vaccine

Jan 22, 2026, 5:00 PM EST - 3 months ago

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

2026-01-07T11:20:26.000Z - 4 months ago

Needham ups Vaxcyte target, adds to Conviction List

PHAT

2026-01-05T20:30:12.000Z - 4 months ago

Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children

Dec 22, 2025, 8:19 AM EST - 5 months ago

This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.

2025-12-08T12:05:20.000Z - 5 months ago

Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31

Dec 8, 2025, 7:00 AM EST - 5 months ago

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Dec 2, 2025, 1:20 PM EST - 5 months ago

Vaxcyte Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 19, 2025, 9:30 AM EST - 6 months ago

Vaxcyte Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 2:30 PM EST - 6 months ago

Vaxcyte Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-04T21:20:25.000Z - 6 months ago

Vaxcyte reports Q3 EPS ($1.56), consensus ($1.25)

Nov 4, 2025, 4:05 PM EST - 6 months ago

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

2025-10-16T11:45:29.000Z - 7 months ago

Vaxcyte price target lowered to $85 from $160 at BTIG

2025-09-30T12:41:15.000Z - 8 months ago

Vaxcyte to establish fill-finish manufacturing in North Carolina

TMO

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Sep 3, 2025, 2:45 PM EDT - 8 months ago

Vaxcyte Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Jun 10, 2025, 1:20 PM EDT - 1 year ago

Vaxcyte Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Vaxcyte Transcript: Jefferies Global Life Sciences Conference

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference 2025

May 13, 2025, 11:40 AM EDT - 1 year ago

Vaxcyte Transcript: BofA Securities 2025 Healthcare Conference

May 7, 2025, 4:01 PM EDT - 1 year ago

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Apr 7, 2025, 1:30 PM EDT - 1 year ago

Vaxcyte Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 6:21 PM EDT - 1 year ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Transcript: Study Result

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 30, 2025, 5:00 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Vaxcyte Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 1:50 PM EST - 1 year ago

Vaxcyte Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:30 PM EST - 1 year ago

Vaxcyte Earnings Call Transcript: Q4 2024

Feb 25, 2025, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 6, 2025, 9:30 AM EST - 1 year ago

Vaxcyte Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Jan 30, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 11:51 AM EST - 1 year ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Dec 3, 2024, 12:30 PM EST - 1 year ago

Vaxcyte Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Nov 20, 2024, 5:00 AM EST - 1 year ago

Vaxcyte Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 1:30 PM EST - 1 year ago

Vaxcyte Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 7:30 AM EST - 1 year ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 5, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 18, 2024, 10:20 AM EDT - 1 year ago

Vaxcyte Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 9:07 AM EDT - 1 year ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 5, 2024, 1:22 AM EDT - 1 year ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 3, 2024, 10:48 AM EDT - 1 year ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:10 AM EDT - 1 year ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 9:24 AM EDT - 1 year ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 1 year ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Vaxcyte Transcript: Study Result

Sep 3, 2024, 7:07 AM EDT - 1 year ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Jul 2, 2024, 8:30 AM EDT - 2 years ago

Vaxcyte Appoints John Furey to Board of Directors

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Vaxcyte Transcript: Jefferies Global Healthcare Conference

May 14, 2024, 12:20 PM EDT - 2 years ago

Vaxcyte Transcript: Bank of America Health Care Conference 2024

May 8, 2024, 4:05 PM EDT - 2 years ago

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 9, 2024, 12:45 PM EDT - 2 years ago

Vaxcyte Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 12, 2024, 8:40 AM EDT - 2 years ago

Vaxcyte Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 5, 2024, 2:10 PM EST - 2 years ago

Vaxcyte Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 8:30 AM EST - 2 years ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Feb 27, 2024, 4:30 PM EST - 2 years ago

Vaxcyte Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:01 PM EST - 2 years ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 4:05 PM EST - 2 years ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 8, 2024, 10:00 AM EST - 2 years ago

Vaxcyte Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 2, 2024, 6:39 PM EST - 2 years ago

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CapitalMonk May. 13 at 4:32 AM

0 · Reply

cubie May. 12 at 4:29 PM

$PCVX yea interesting

0 · Reply

RandyRanderson1 May. 12 at 4:00 PM

@cubie $PCVX Any thoughts on the options trading going on here? Looks like the same trader active across the Oct and Dec. Thanks!

1 · Reply

OfficialStocktwitsUser Apr. 10 at 3:02 AM

0 · Reply

NorthStarStats Apr. 1 at 1:45 AM

0 · Reply

greensmell Mar. 7 at 4:42 AM

$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw

0 · Reply

KY3000 Mar. 7 at 12:02 AM

$PCVX HMPV, no vaccine can treat it, this should be their next target

0 · Reply

BillionerOfKing Mar. 3 at 2:34 AM

0 · Reply

KY3000 Feb. 28 at 7:14 PM

$PCVX don’t worry about production

0 · Reply

KY3000 Feb. 25 at 10:34 PM

$PCVX needs to announce another target, they going to be commercialized sooner than later

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:16 AM

$PCVX RSI: 63.50, MACD: 1.9469 Vol: 1.77, MA20: 54.85, MA50: 49.71 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 9 at 7:17 PM

$PCVX Share Price: $55.51 Contract Selected: Jul 17, 2026 $55 Calls Buy Zone: $6.54 – $8.09 Target Zone: $11.59 – $14.16 Potential Upside: 67% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Feb. 5 at 5:19 AM

$PCVX RSI: 64.71, MACD: 2.4385 Vol: 3.94, MA20: 50.53, MA50: 47.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BuffettStyleInvestments Feb. 4 at 11:54 AM

$PCVX is a vaccine developer with a promising pneumococcal candidate; its valuation is binary on phase 3 data and potential market disruption of entrenched players.

0 · Reply

CC01 Jan. 30 at 6:10 PM

$PCVX Strong buy

0 · Reply

KY3000 Jan. 23 at 3:17 PM

$STRO if you believe in $PCVX, than 300$ mill in milestones is a lock

0 · Reply

Night_Owl_Biotech Jan. 23 at 2:15 AM

The XBI is up 6% over the last 3 trading sessions. The XBI held 145 bio focused stocks as of Tuesday 1/20/2026. Attached is a schedule of the largest gains (by dollar) & all stocks down over the last 3 days. 124 of the 145 or 86% of these bio stocks have traded higher. 1 is unchanged & only 20 are down. $MRNA & $CRVS have produced the largest dollar gains for the XBI over the last 3 days. $PRAX is off the most by $ value (though is up 500% since reporting the data from their movement disorder therapy). PRAX has raised over $1B over the last 3 months. We believe $PCVX will eventually be acquired by $PFE

0 · Reply

theCATALYST Jan. 22 at 9:13 PM

$ARVN $PCVX $SLDB +89% / +66% / +123%

0 · Reply

samiztech2022 Jan. 21 at 7:02 PM

$PCVX on the move, next $JELD , NFA

0 · Reply

Ariad Jan. 21 at 6:00 PM

$PCVX Analyst say big upside on this vaccine name. And Nice chart and good price action during volatility. $TSLA $RUN

0 · Reply

Market Cap	7.80B
Revenue (ttm)	0.00
Net Income (ttm)	-766.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,260,700
Avg Vol	1,364,064
Day's Range	N/A - N/A
Shares Out	144.40M
Stochastic %K	50%
Beta	1.30
Analysts	Strong Sell
Price Target	$109.00